Boardroom Alpha
Boardroom Alpha
SKIN · Additional Proxy Materials (DEFA14A) · Filed August 12, 2026

Skinhealth Systems Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
August 12, 2026
Ticker
SKIN
Accession
0001683168-26-006276
Boardroom Alpha · Filing insights

SkinHealth's board urges stockholders to approve the reverse stock split and adjournment at the 2026 special meeting.

About Skinhealth Systems Inc
Market cap
$85M
1Y TSR
−66.3%
3Y TSR
−53.5%
Board grade
C-
Sector
Consumer Defensive
CEO
Pedro Bruno Ferreira Malha
Last annual meeting: Sep 22, 2026 · View full Skinhealth Systems Inc profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

Schedule 14A

 

 

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION

 

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

 

Filed by the Registrant
   
Filed by a party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement
   
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
Definitive Proxy Statement
   
Definitive Additional Materials
   
Soliciting Material Pursuant to §240.14a-12

 

SkinHealth Systems Inc.

(Name of Registrant as Specified in its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

No fee required
   
Fee paid previously with preliminary materials
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

   

 

 

 

 

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # T03132 - S46541 *Please check the meeting materials for any special requirements for meeting attendance. You invested in SKINHEALTH SYSTEMS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Special Stockholders’ Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on September 22, 2026. Get informed before you vote View the Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 8, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. SKINHEALTH SYSTEMS INC. 2026 Special Stockholders’ Meeting Vote by September 21, 2026 11:59 PM ET Virtually at: www.virtualshareholdermeeting.com/SKIN2026SM SKINHEALTH SYSTEMS INC. 3600 E. BURNETT ST. LONG BEACH, CA 90815 Vote Virtually at the Meeting* September 22, 2026 8:00 a.m. PDT

   

 

 

 

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. For 1 . To approve an amendment to our Restated Certificate of Incorporation to combine outstanding shares of our Class A Common Stock, par value $ 0 . 0001 per share, into a lesser number of outstanding shares, by a ratio of not less than 1 - for - 5 and not more than 1 - for - 20 , with the exact ratio to be set within this range by our board of directors in its sole discretion (the “Reverse Stock Split Proposal” or “Proposal No . 1 ”) . For 2 . To approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and voting of proxies in the event that there are insufficient votes in favor of Proposal No . 1 or if there are insufficient shares present to establish a quorum (the “Adjournment Proposal” or “Proposal No . 2 ”) . Voting Items Board Recommends T03133 - S46541

   

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Skinhealth Systems Inc (SKIN)

Reference

Frequently asked questions

When did Skinhealth Systems Inc file this DEFA14A?
Skinhealth Systems Inc (SKIN) filed this Additional Proxy Materials (DEFA14A) with the SEC on August 12, 2026. The accession number assigned by EDGAR is 0001683168-26-006276.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
SkinHealth's board urges stockholders to approve the reverse stock split and adjournment at the 2026 special meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Skinhealth Systems Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Skinhealth Systems Inc has filed under CIK 1818093, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer